Focus: Millicent Pharma is a specialty pharmaceutical company headquartered in Dundalk, Ireland, focused on women's health with a concentrated portfolio in menopausal treatments. The company derives 99% of revenue from FEMRING, indicating a single-product-dependent business model.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Millicent Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Millicent Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Company flagship generating 99% of revenue; approaching loss of exclusivity creates material revenue cliff risk.
Help build intelligence for Millicent Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Secondary asset at peak stage with 2031 LOE; minimal current revenue but represents company's only significant future cliff.
Post-LOE generic oral contraceptive with no disclosed Part D spending; likely low-margin commodity asset.
Post-LOE generic oral contraceptive with no disclosed Part D spending; likely low-margin commodity asset.
Low-priority estradiol acetate asset with approaching LOE; minimal revenue signal.
Newest asset in growth phase with extended 2041 LOE; likely represents company's commercial development focus in contraception.
1 discontinued, 2 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo